VAXCYTE, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
VAXCYTE, INC. (PCVX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 15.41 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- VAXCYTE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 15.41M shares, a 16.22% increase year-over-year.
- VAXCYTE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 15.51M shares, a 21.87% increase year-over-year.
- VAXCYTE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 14.21M shares, a 32.54% increase year-over-year.
- VAXCYTE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 13.26M shares, a 17.66% increase year-over-year.
- VAXCYTE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.47M shares, a 25.15% increase from fiscal 2024.
- VAXCYTE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 11.57M shares, a 13.29% increase from fiscal 2023.
- VAXCYTE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 10.21M shares, a 22.67% increase from fiscal 2022.
- VAXCYTE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 8.32M shares, a 53.44% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 15.41M shares 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | 15.51M shares 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | 14.47M shares 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | 14.21M shares 10-Q · filed 2025-11-04 | 14.56M shares 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 13.26M shares 10-Q · filed 2026-08-05 | 13.26M shares 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 12.73M shares 10-Q · filed 2026-05-06 | ||||
| 2024-12-31 | 11.57M shares 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | 10.72M shares 10-Q · filed 2025-11-04 | 10.72M shares 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 11.27M shares 10-Q · filed 2025-08-06 | 11.27M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 12.61M shares 10-Q · filed 2025-05-07 | ||||
| 2023-12-31 | 10.21M shares 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | 10.10M shares 10-Q · filed 2024-11-05 | ||||
| 2023-06-30 | 10.25M shares 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | 10.07M shares 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | 8.32M shares 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | 8.18M shares 10-Q · filed 2023-11-06 | ||||
| 2022-06-30 | 7.77M shares 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | 7.23M shares 10-Q · filed 2023-05-08 | ||||
| 2021-12-31 | 5.42M shares 10-K · filed 2024-02-27 | 5.36M shares 10-K · filed 2022-02-28 | |||
| 2021-09-30 | 5.56M shares 10-Q · filed 2022-11-07 | ||||
| 2021-06-30 | 5.89M shares 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | 4.86M shares 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | 5.28M shares 10-K · filed 2023-02-27 | 5.19M shares 10-K · filed 2021-03-29 | |||
| 2020-09-30 | 5.09M shares 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | 5.17M shares 10-Q · filed 2020-08-12 | ||||
| 2020-03-31 | 32.17M shares 10-Q · filed 2021-05-11 | ||||
| 2019-12-31 | 23.85M shares 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | 19.86M shares 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | 20.10M shares 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | 19.83M shares 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |